Empowered Patient Podcast

Eric Rock is the Founder and CEO of Vivify Health and a pioneer in the application of remote patient monitoring, consumer electronics, and biometric devices combined with virtual visits to connect patients and providers outside the hospital setting.

Eric explains, "Fortunately, Vivify, from our beginning days, created a solution that encompassed a connected tablet with a very unique and simple experience that spoke to the patient and connected to the provider. It made it incredibly simple regardless of your age. With an average age of 77 across our customer base, where that product was applied to, we knew this market well. And many were entering the market saying, "Okay, well, I can just give them an app to download." Well, that's a very quick failure in that population."

"So, understanding the complexities of distributing devices to patients that we're all responsible for and even getting those devices returned in most cases is a big part of the services and value that Vivify brings to the table. So it is a very simple solution for seniors with all of that backend technology support logistics, and an incredible experience for the provider as well. It's simple for everybody involved as it would be for an in-person visit, while at the same time we manage all of that technology headache. And we've done that very well for over a decade."

@VivifyHealth @ericlrock #DigitalHealth #telehealth #telemedicine #remotepatientmonitoring #RPM #VirtualHealthcare

VivifyHealth.com

Listen to the podcast here

Eric Rock is the Founder and CEO of Vivify Health and a pioneer in the application of remote patient monitoring, consumer electronics, and biometric devices combined with virtual visits to connect patients and providers outside the hospital setting.

Eric explains, "Fortunately, Vivify, from our beginning days, created a solution that encompassed a connected tablet with a very unique and simple experience that spoke to the patient and connected to the provider. It made it incredibly simple regardless of your age. With an average age of 77 across our customer base, where that product was applied to, we knew this market well. And many were entering the market saying, "Okay, well, I can just give them an app to download." Well, that's a very quick failure in that population."

"So, understanding the complexities of distributing devices to patients that we're all responsible for and even getting those devices returned in most cases is a big part of the services and value that Vivify brings to the table. So it is a very simple solution for seniors with all of that backend technology support logistics, and an incredible experience for the provider as well. It's simple for everybody involved as it would be for an in-person visit, while at the same time we manage all of that technology headache. And we've done that very well for over a decade."

@VivifyHealth @ericlrock #DigitalHealth #telehealth #telemedicine #remotepatientmonitoring #RPM #VirtualHealthcare

VivifyHealth.com

Download the transcript here

Craig Parker is the Chief Executive Officer at Surrozen. Their research in the Wnt pathway and proteins identified these are critical to maintaining tissues in our body and are found in tissues as diverse as the lung, intestine, liver, sensory hair cells, and the eye. The company is first targeting a patient population with a severe alcoholic injury to the liver who are not eligible for transplant but would benefit from regeneration in their liver.

Craig explains, "It really starts with a signal outside the cell that gets transmitted inside the cell by this Wnt signaling pathway, which in turn activates a number of genes that are responsible for these processes, like tissue repair or embryonic development, or renewal of stem cells."

"The Wnt proteins actually don't dissolve very well in the circulation, and they really only act within a few cells distance from where they're produced. What made this pathway very difficult to try to modulate for therapeutic use is that these proteins, you can't just copy one of these proteins and inject it and have it activate this path in a distanced cell. These proteins are quite unique in the way they only work one or two cells away from where they're produced."

#Surrozen #wntpathway #wntproteins

Surrozen.com

Listen to the podcast here

Craig Parker is the Chief Executive Officer at Surrozen. Their research in the Wnt pathway and proteins identified these are critical to maintaining tissues in our body and are found in tissues as diverse as the lung, intestine, liver, sensory hair cells, and the eye. The company is first targeting a patient population with a severe alcoholic injury to the liver who are not eligible for transplant but would benefit from regeneration in their liver.

Craig explains, "It really starts with a signal outside the cell that gets transmitted inside the cell by this Wnt signaling pathway, which in turn activates a number of genes that are responsible for these processes, like tissue repair or embryonic development, or renewal of stem cells."

"The Wnt proteins actually don't dissolve very well in the circulation, and they really only act within a few cells distance from where they're produced. What made this pathway very difficult to try to modulate for therapeutic use is that these proteins, you can't just copy one of these proteins and inject it and have it activate this path in a distanced cell. These proteins are quite unique in the way they only work one or two cells away from where they're produced."

#Surrozen #wntpathway #wntproteins

Surrozen.com

Download the transcript here

Dr. Richard Watson is a Co-Founder of Motient and has taken on the challenge of creating an efficient solution to solve the puzzle of how to move patients from one place to another with a focus on rural healthcare and rural hospitals. Motient was founded as a medical transport company that did air and ground transport. They have now created Mission Control which is even more critical in this time of the Delta resurgence to help manage decisions in the care of all patients.

Richard says, "The sending facility environment is different than the receiving facility. That's different from the EMS transport people. And everybody's got their head down doing solid work, but the idea that we could actually link arms and make that work better, improve the outcomes, improve patient care. I don't think that was something that was the focus. I mean, we're too busy measuring other things in the system to understand how that affects patient care. But every aspect of quality and sustainability is affected how patients move in the system."

#PatientTransfer #RuralHealth #RuralHealthCare #RuralHospitals #Healthcare #EmergencyMedicine #HealthIT

Motient.io

Listen to the podcast here

Dr. Richard Watson is a Co-Founder of Motient and has taken on the challenge of creating an efficient solution to solve the puzzle of how to move patients from one place to another with a focus on rural healthcare and rural hospitals. Motient was founded as a medical transport company that did air and ground transport. They have now created Mission Control which is even more critical in this time of the Delta resurgence to help manage decisions in the care of all patients.

Richard says, "The sending facility environment is different than the receiving facility. That's different from the EMS transport people. And everybody's got their head down doing solid work, but the idea that we could actually link arms and make that work better, improve the outcomes, improve patient care. I don't think that was something that was the focus. I mean, we're too busy measuring other things in the system to understand how that affects patient care. But every aspect of quality and sustainability is affected how patients move in the system."

#PatientTransfer #RuralHealth #RuralHealthCare #RuralHospitals #Healthcare #EmergencyMedicine #HealthIT

Motient.io

Download the transcript here

David Katz is the Chief Scientific Officer at Sparrow Pharmaceuticals. He is exploring the possibility of blocking the formation of intracellular steroids to reduce the side effects of steroid medicines and conditions related to the overproduction of cortisol in the body in such diseases as Cushing's Syndrome and autonomous cortisol secretion.

David says, "Cortisol is made in an organ called the adrenal, and then it circulates throughout the body. And endocrinologists tend to think about the cortisol that's circulating as really being the effector of both the good effects, so immune suppression that you want in a patient who has a transplanted organ or an autoimmune disease, as well as all the bad effects."

"What we recognize actually is that most of the receptors of cortisol are within the cell and that it's the steroid that's in the cell that matters. And most of that actually is made by a different pathway, by an enzyme called HSD1, which is the target of our drug."

"And the magic of that is the immune suppressive actions of the steroids almost uniquely seem to be dependent on systemic steroids more than the intracellular steroids. And so, by blocking the formation of this pool of intracellular steroids by inhibiting HSD1, we can block many of the bad effects without necessarily meaningfully altering the desired effect in patients who are taking steroid medicines."

@SparrowPharma #Steroids #Corticosteroids #Cortisol #CushingsSyndrome #PolymyalgiaRheumatica #IntracellularSteroids #RareDiseases

SparrowPharma.com

Listen to the podcast here

David Katz is the Chief Scientific Officer at Sparrow Pharmaceuticals. He is exploring the possibility of blocking the formation of intracellular steroids to reduce the side effects of steroid medicines and conditions related to the overproduction of cortisol in the body in such diseases as Cushing's Syndrome and autonomous cortisol secretion.

David says, "Cortisol is made in an organ called the adrenal, and then it circulates throughout the body. And endocrinologists tend to think about the cortisol that's circulating as really being the effector of both the good effects, so immune suppression that you want in a patient who has a transplanted organ or an autoimmune disease, as well as all the bad effects."

"What we recognize actually is that most of the receptors of cortisol are within the cell and that it's the steroid that's in the cell that matters. And most of that actually is made by a different pathway, by an enzyme called HSD1, which is the target of our drug."

"And the magic of that is the immune suppressive actions of the steroids almost uniquely seem to be dependent on systemic steroids more than the intracellular steroids. And so, by blocking the formation of this pool of intracellular steroids by inhibiting HSD1, we can block many of the bad effects without necessarily meaningfully altering the desired effect in patients who are taking steroid medicines."

@SparrowPharma #Steroids #Corticosteroids #Cortisol #CushingsSyndrome #PolymyalgiaRheumatica #IntracellularSteroids #RareDiseases

SparrowPharma.com

Download the transcript here

Hideki Garren MD Ph.D. is the Chief Medical Officer at Prothena with a mission to advance the pipeline of candidates for neurodegenerative and protein amyloid diseases, including Alzheimer's and Parkinson's. We talk about the recent FDA approval of aducanumab and its impact on research.

Hideki says, "As we've shown at the AAIC, the Alzheimer's Association International Conference last week in Denver, we highlighted two out of three of our Alzheimer's disease potential treatments. One of them is PRX012, which is our anti-Aβ antibody. The second one that we showed there was a dual, Aβ-tau vaccine. And then thirdly, we have an anti-tau antibody, which is being developed. It was not shown at the AAIC, but we're also developing that. So these three molecules we're developing for Alzheimer's disease. And this momentum has really applied to us as well."

#Prothena #Alzheimers #aduhelm #ProteinAmyloidDiseases #NeurodegenerativeDiseases #Vaccines #AAIC21

Prothena.com

Listen to the podcast here

Hideki Garren MD Ph.D. is the Chief Medical Officer at Prothena with a mission to advance the pipeline of candidates for neurodegenerative and protein amyloid diseases, including Alzheimer's and Parkinson's. We talk about the recent FDA approval of aducanumab and its impact on research.

Hideki says, "As we've shown at the AAIC, the Alzheimer's Association International Conference last week in Denver, we highlighted two out of three of our Alzheimer's disease potential treatments. One of them is PRX012, which is our anti-Aβ antibody. The second one that we showed there was a dual, Aβ-tau vaccine. And then thirdly, we have an anti-tau antibody, which is being developed. It was not shown at the AAIC, but we're also developing that. So these three molecules we're developing for Alzheimer's disease. And this momentum has really applied to us as well."

#Prothena #Alzheimers #aduhelm #ProteinAmyloidDiseases #NeurodegenerativeDiseases #Vaccines #AAIC21

Prothena.com

Download the transcript here